Company
A clinical-stage biotechnology company
PEP-Therapy is a Paris-based biotechnology company developing next-generation therapies based on its intracellular drug delivery technology as a shuttle.
Our technology allows to address the intracellular undruggable space with multiple payloads such as peptides, proteins, antibodies, or nucleic acids.
As a demonstrator, PEP-010, our first drug candidate developed in oncology, is a pro-apoptotic peptide which has shown anti-tumoral activity and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy.
+ PRODUCTS
OUR MISSION
PEP-Therapy develops next-generation intracellular targeted therapies, improving drug performance with efficient cell delivery.
OUR VISION
Become a global reference in smart cell-penetrating medicines that transform patient outcomes, through strategic partnerships.
Backed by international investors
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, CapHorn, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).
Our partners
Our partners